Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.
Guided Therapeutics Trading Down 17.2%
OTCMKTS GTHP opened at $0.24 on Friday. The firm has a market cap of $23.17 million, a PE ratio of -6.00 and a beta of 0.71. Guided Therapeutics has a 1-year low of $0.15 and a 1-year high of $0.54. The stock has a 50-day moving average of $0.26 and a 200-day moving average of $0.27.
About Guided Therapeutics
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
Further Reading
- Five stocks we like better than Guided Therapeutics
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
